Lyfjos® - a partner in generating, assessing and commercialization of intellectual property and derived products.
Aimed at the needs of researchers to extend the scope of their discoveries, Lyfjos is contribution building up a portfolio of promising IP and bringing them to market. Lyfjos is focusing projects that result in defined tangible assets in known markets.
Lyfjos’ research focusses mainly on blood disorders. A focus was laid to produce inexpensive and robust treatments and diagnosing tools that can be made available everywhere. Along with the treatments, Lyfjos is committed to develop suitable diagnosing and monitoring tools.
Together with the University Hospital of Zurich and the University of Zurich, Lyfjos successfully concluded a clinical phase II study assessing the the use of the drug Memantine for Sickle Cell Disease patients. With this study, we gained clear indication that the proposed treatment is efficient.
About Sickle Cell Diesease:
“The World Health Organization has declared Sickle Cell Anemia, the most prevalent genetic disease in Africa, a public health priority. In the WHO African Region, 10% to 40 % of the population carries the sickle cell trait leading to sickle cell disease prevalence of around 2 %. The burden of sickle cell disease is increasing with the currently observed population growth on the African continent.
Children under five, adolescent and pregnant women are mostly affected by sickle cell disease related premature deaths. Most of the affected countries are resource pour and are facing major challenges to devote appropriate resources in their health care systems to attend to the special needs of these people. In 2010, WHO has called for joint action from the international community to tackle this highly neglected disease.” – Dr. med. vet. Claudia Daubenberger